Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Frequent Blood Donations Safe for Some, But Not AllDrone Sets New Record for Transporting Blood SamplesGun Injuries Add Millions of Dollars to Hospital CostsACP Does Not Support Legalization of Assisted SuicideAAP: Few Doctors Provide Firearm Injury Prevention Info in ER9 of 10 Docs Unprepared to Prescribe MarijuanaThis Mistake Can Cost Athletes' Lives in Cardiac ArrestDrills Assess ER Response to Communicable DiseaseDo Nursing Home Workers Change Gloves Often Enough?Minorities Exposed to Dirtier Air, U.S. Study FindsPhysicians Tweeting About Drugs May Have Conflict of Interest'Science Spin' Found Prevalent in Biomedical LiteratureHealth Tip: Overcoming the Obesity EpidemicU.S. Military Surgeons Helped More Than 6,000 Afghan AdultsWhat You Can Do to Help Fight the Opioid EpidemicAre Physicians Obligated to Help on Planes?Median Cost of Cancer Drug Development $648.0 MillionDoes Study Claim a Cure? Beware of Scientific 'Spin'Vaccine Campaign in Poor Countries to Save 20 Million LivesThird Dose of MMR Vaccine Could Help Curb Mumps OutbreaksDocs Should Be Aware of Family Beliefs Regarding NondisclosureIncrease in Medical Exemptions From Immunization in CaliforniaMailed Invitations Increase CRC Screening CompletionMany Americans Getting Medical Care They Don't NeedInsurer Aetna's Envelopes Revealed Customers' HIV StatusHealth Groups Demand 'R' Rating for Movies That Show SmokingGoogle Search for 'Depression' Now to Provide Screening TestPatients' Hearing Loss May Mean Poorer Medical CareFDA May Limit 'Risk Info' in Direct-to-Consumer TV Drug AdsFDA Announces Recall of Some Liquid Pharmaceutical ProductsIs FDA Taking Close Enough Look at Fast-Tracked Drugs?Steep Price Hikes Led to Drop in Use of 2 Heart Drugs at U.S. HospitalsAPA: Medical Discrimination Based on Size Stresses Patients2 of 3 U.S. Patients Keep Unused Painkillers After SurgeryMedical Reality Catches Up to Science FictionFDA Looks to Reduce Nicotine in CigarettesAHA Hands-Only CPR Training Kiosks Available at More Airports$100 Sweetens the Pot for a ColonoscopyJust a Few Vaccine Refusers Could Endanger ManyASCO Addresses Cancer Drug PricingHigh Court Rules Against Interstate Medical LiabilityFewer U.S. Dollars Spent on Cardiac Arrest Research: StudyPainkiller Prescriptions More Prone to Errors If HandwrittenFDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.Walking Rates Are Key to a Country's Obesity LevelsDocs Should Counsel Even Healthy People on Diet, Exercise, Experts SayHealth Service Use Unchanged From 1996-1997 to 2011-2012Easier Colon Exam Boosts Screening, But Insurers May Not PayMore U.S. Patients Are Recording Their Doctor VisitsMedication Mistakes Have Doubled in U.S. Since 2000: Study
Questions and AnswersLinksBook Reviews
Related Topics

FDA Asks Maker of Opioid Painkiller Opana ER to Pull Drug From Market

HealthDay News
by -- Robert Preidt
Updated: Jun 9th 2017

new article illustration

FRIDAY, June 9, 2017 (HealthDay News) -- Sales of reformulated Opana ER, a prescription opioid painkiller, should be halted in the United States, the U.S. Food and Drug Administration says.

In its request Thursday for Endo Pharmaceuticals to voluntarily withdraw the drug, the FDA said the benefits of the drug may no longer outweigh the risk of abuse. It's the first time the FDA has moved to take an opioid pain medication off the market due to the public health threat of abuse.

The FDA's analysis of data gathered after the drug was approved showed that injection abuse of reformulated Opana ER (oxymorphone hydrochloride) was linked with a serious outbreak of HIV and hepatitis C, as well as cases of a serious blood disorder called thrombotic microangiopathy.

In March 2017, an FDA advisory committee concluded that the benefits of reformulated Opana ER no longer outweigh its risks.

"We are facing an opioid epidemic -- a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse," FDA Commissioner Dr. Scott Gottlieb said in an agency news release.

"We will continue to take regulatory steps when we see situations where an opioid product's risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse," he added.

Addiction to prescription opioids, which include oxycodone (Oxycontin, Percocet) and hydrocodone (Vicoprofen), is a growing epidemic in the United States. The number of opioid overdose deaths has quadrupled in the past 15 years, health officials report.

Opana ER was first approved in 2006 for the management of moderate-to-severe pain in patients who required an around-the-clock opioid for an extended period of time. In 2012, Endo replaced the original formulation of Opana ER with a new formulation intended to make the drug resistant to physical and chemical manipulation for abuse by snorting or injecting.

However, the FDA has concluded that the reformulation can't meaningfully reduce abuse of the drug.

"The abuse and manipulation of reformulated Opana ER by injection has resulted in a serious disease outbreak. When we determined that the product had dangerous unintended consequences, we made a decision to request its withdrawal from the market," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in the news release.

If Endo does not voluntarily remove reformulated Opana ER from the market, the FDA said it would withdraw approval of the drug.

Until Opana ER is taken off the market, the FDA is warning health care professionals and others of the serious risks associated with abuse of the drug.

In a statement, Endo said it's "reviewing the request and is evaluating the full range of potential options."

More information

The U.S. National Institute on Drug Abuse outlines the signs of pain medicine abuse and addiction.